Keay Nakae Analyst Performance

Senior Research Analyst, Small RNA, Microbiome, Digital Therapeutics at Chardan Capital

Keay Nakae is a stock analyst at Chardan Capital focused in the medical sector, covering 40 publicly traded companies. Over the past year, Keay Nakae has issued 50 stock ratings, including buy and hold recommendations. While full access to Keay Nakae's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Keay Nakae's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 147 Last 9 Years
Buy Recommendations: 93.20% 137 Buy Ratings
Companies Covered: 40 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	93.2%	137 ratings
Hold	6.1%	9 ratings
Sell	0.7%	1 ratings

Out of 147 total stock ratings issued by Keay Nakae at Chardan Capital, the majority (93.2%) have been Buy recommendations, followed by 6.1% Hold and 0.7% Sell.

Best & Worst Calls

Best Call
000000.0%
OCGN
Jun 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
0000.0%
KLDO
Nov 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.5% of companies on NASDAQ	37 companies
NYSE	5.0% of companies on NYSE	2 companies
NYSEAMERICAN	2.5% of companies on NYSEAMERICAN	1 company

Keay Nakae, an analyst at Chardan Capital, currently covers 40 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 39 companies	97.5%
	Miscellaneous 1 company	2.5%

Keay Nakae of Chardan Capital specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 19 companies	47.5%
PHARMACEUTICAL PREPARATIONS 7 companies	17.5%
MED - DRUGS 4 companies	10.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	5.0%
BIOTECHNOLOGY 1 company	2.5%
MED PRODUCTS 1 company	2.5%
MEDICAL SERVICES 1 company	2.5%
DIAGNOSTICS & RESEARCH 1 company	2.5%
MISCELLANEOUS HEALTH & ALLIED SERVICES 1 company	2.5%
SURGICAL & MEDICAL INSTRUMENTS 1 company	2.5%
MED INSTRUMENTS 1 company	2.5%
Miscellaneous 1 company	2.5%

About Keay Nakae

Keay Nakae is a Senior Research Analyst at Chardan. Mr. Nakae has over 17 years of experience as a sell-side research analyst covering healthcare companies, and has previously worked at Wedbush Morgan, and CE Unterberg Towbin/Collins Stewart. Mr. Nakae has made numerous media appearances on Bloomberg TV, and has been quoted in publications such as The Wall Street Journal, Time, Business Week, and The Los Angeles Times. He has been recognized by Forbes magazine in its annual survey of America’s Best Analysts. Mr. Nakae earned an MBA degree from UCLA’s Anderson School of Management, and holds MS and BS degrees in electronic engineering from Cal Poly. Mr. Nakae is a CFA charterholder and a member of the CFA Institute.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RNA Avidity Biosciences	9/10/2025	Reiterated Rating	$47.34	$75.00	Buy
COYA Coya Therapeutics	8/13/2025	Reiterated Rating	$6.02	$14.00	Buy
KRRO Korro Bio	8/13/2025	Reiterated Rating	$18.93	$25.00	Buy
MNPR Monopar Therapeutics	8/13/2025	Reiterated Rating	$33.51	$60.00	Buy
OBIO Orchestra BioMed	8/13/2025	Reiterated Rating	$2.66	$20.00	Buy
ARWR Arrowhead Pharmaceuticals	8/11/2025	Reiterated Rating	$16.42	$60.00	Buy
ABUS Arbutus Biopharma	8/11/2025	Reiterated Rating	$3.40	$5.00	Buy
SABS SAB Biotherapeutics	8/8/2025	Lower Price Target	$2.23	$12.00	Buy
SLN Silence Therapeutics	8/8/2025	Reiterated Rating	$5.38	$35.00	Buy
PRQR ProQR Therapeutics	8/8/2025	Reiterated Rating	$2.05	$4.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
RNA Avidity Biosciences	8/8/2025	Reiterated Rating	$47.52	$75.00	Buy
OBIO Orchestra BioMed	8/7/2025	Reiterated Rating	$2.64	$20.00	Buy
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$392.24	$400.00	Buy
DYN Dyne Therapeutics	7/29/2025	Lower Price Target	$9.31	$38.00	Buy
COYA Coya Therapeutics	7/1/2025	Reiterated Rating	$5.72	$14.00	Buy
IBIO iBio	6/25/2025	Reiterated Rating	$0.75	$5.00	Buy
MNPR Monopar Therapeutics	6/23/2025	Initiated Coverage	$32.86	$60.00	Buy
DYN Dyne Therapeutics	6/17/2025	Reiterated Rating	$11.48	$50.00	Buy
SLN Silence Therapeutics	6/13/2025	Reiterated Rating	$5.59	$35.00	Buy
RNA Avidity Biosciences	6/9/2025	Boost Price Target	$33.13	$75.00	Buy
SABS SAB Biotherapeutics	5/15/2025	Reiterated Rating	$2.01	$20.00	Buy
ARWR Arrowhead Pharmaceuticals	5/13/2025	Reiterated Rating	$13.97	$60.00	Buy
OBIO Orchestra BioMed	5/13/2025	Reiterated Rating	$2.94	$20.00	Buy
COYA Coya Therapeutics	5/13/2025	Reiterated Rating	$5.76	$14.00	Buy
DYN Dyne Therapeutics	5/9/2025	Reiterated Rating	$11.32	$50.00	Buy
SLN Silence Therapeutics	5/9/2025	Lower Price Target	$3.56	$35.00	Buy
MCRB Seres Therapeutics	5/8/2025	Reiterated Rating	$8.29	$6.00	Neutral
RNA Avidity Biosciences	5/7/2025	Reiterated Rating	$26.26	$65.00	Buy
IBIO iBio	5/5/2025	Reiterated Rating	$1.01	$5.00	Buy
ALNY Alnylam Pharmaceuticals	5/2/2025	Boost Price Target	$255.13	$325.00	Buy
COYA Coya Therapeutics	4/28/2025	Reiterated Rating	$6.18	$14.00	Buy
OBIO Orchestra BioMed	4/22/2025	Reiterated Rating	$2.90	$20.00	Buy
KRRO Korro Bio	4/16/2025	Initiated Coverage	$13.40	$25.00	Buy
SONN Sonnet BioTherapeutics	4/7/2025	Reiterated Rating	$1.25	$20.00	Buy
SABS SAB Biotherapeutics	4/1/2025	Lower Price Target	$1.40	$20.00	Buy
OBIO Orchestra BioMed	4/1/2025	Reiterated Rating	$3.24	$20.00	Buy
GANX Gain Therapeutics	3/28/2025	Reiterated Rating	$2.07	$6.00	Buy
ABUS Arbutus Biopharma	3/28/2025	Reiterated Rating	$3.27	$5.00	Buy
SONN Sonnet BioTherapeutics	3/28/2025	Reiterated Rating	$1.31	$20.00	Buy
ALNY Alnylam Pharmaceuticals	3/21/2025	Reiterated Rating	$253.60	$300.00	Buy

COYA Coya Therapeutics	3/20/2025	Reiterated Rating	$6.45	$14.00	Buy
MCRB Seres Therapeutics	3/20/2025	Reiterated Rating	$14.64	$25.00	Buy
DYN Dyne Therapeutics	3/17/2025	Reiterated Rating	$12.22	$50.00	Buy
PRQR ProQR Therapeutics	3/14/2025	Reiterated Rating	$1.74	$4.00	Buy
DYN Dyne Therapeutics	2/28/2025	Reiterated Rating	$13.30	$50.00	Buy
ALNY Alnylam Pharmaceuticals	2/26/2025	Reiterated Rating	$245.20	$300.00	Buy
ARWR Arrowhead Pharmaceuticals	2/11/2025	Reiterated Rating	$19.92	$60.00	Buy
COYA Coya Therapeutics	2/6/2025	Reiterated Rating	$7.00	$14.00	Buy
SABS SAB Biotherapeutics	1/29/2025	Reiterated Rating	$2.28	$25.00	Buy
DYN Dyne Therapeutics	1/10/2025	Reiterated Rating	$15.46	$50.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.